Trials / Completed
CompletedNCT04307173
Study of Multiple Ascending Dose of KBL693 in Healthy Participants
A Phase I Randomised Double-Blind Placebo-Controlled Study of Multiple Ascending Dose of KBL693 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- KoBioLabs · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..
Detailed description
This is a randomized, double-blind, placebo-controlled, single centre Phase I study. Eighteen (18) subjects are planned to be randomised at 1 site across the 2 parts of the study as follows: * Cohort 1: 680 mg/day * Cohort 2: 6800 mg/day
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KBL693 | Part 1: 680 mg/day of KBL693 or Placebo; Route of Administration: Oral |
| DRUG | KBL693 | Part 2: 6800 mg/day of KBL693 or Placebo; Route of Administration: Oral |
Timeline
- Start date
- 2020-08-14
- Primary completion
- 2020-10-30
- Completion
- 2020-11-12
- First posted
- 2020-03-13
- Last updated
- 2021-02-21
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04307173. Inclusion in this directory is not an endorsement.